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Background: Epidemiological studies investigating a possible association between 
bisphosphonates and atrial fibrillation (AF) have reported conflicting findings. The objective 
of our study was to determine whether exposure to oral nitrogen-containing bisphosphonates 
alendronate and risedronate are associated with increased incidence of atrial fibrillation.
Methods: In a retrospective cohort study we analyzed data from three large independent 
databases, two from the United States (MarketScan® and Ingenix®) and one from the United 
Kingdom (THIN). 144,548 women, age 50–89, bisphosphonate users during 2002–2005 were 
compared to 668,891 sex- and age-matched controls (1:4). Our primary outcome measure was 
new incident atrial fibrillation for up to three years; Cox models adjusted for disease and drug 
history were used to estimated relative risks.
Results: We identified a total of 8,001, 1,984, and 817 AF cases in oral bisphosphonate users 
and nonusers during 744,340 (MarketScan), 243,898 (Ingenix), and 148,779 (THIN) person-
years of follow-up, respectively. Compared to nonusers, overall adjusted relative risk (adjRR) 
(95% confidence interval [CI]) for AF in oral bisphosphonates users was 0.92 (0.85–0.99; 
MarketScan), 1.00 (0.87–1.16; Ingenix), and 0.97 (0.79–1.20; THIN); overall adjRR (95% CI) 
for any cardiac dysrrhythmia for MarketScan was 1.01 (0.98–1.05), Ingenix 1.06 (0.99–1.13), 
and THIN 0.97 (0.79–1.20).
Conclusions: In all three databases from the two countries, the risk of AF or cardiac 
dysrrhythmia was not increased in postmenopausal women treated for up to three years with 
oral alendronate or risedronate.
Keywords: atrial fibrillation, chemically induced osteoporosis, drug therapy, alendronate or 
risedronate, bisphosphonates, adverse effects
Introduction
Concerns about a possible association of bisphosphonates with events of atrial 
fibrillation (AF), the most common cardiac arrhythmia, were initially prompted by 
the  HORIZON Pivotal Fracture Trial,1 which showed a greater incidence of serious 
AF adverse events among women treated with once-yearly intravenous zoledronic 
acid compared to placebo controls. In the similarly designed HORIZON Recurrent 
Fracture Trial, however, no excess of cardiac arrhythmias, including AF, was seen 
in patients treated with zoledronic acid.2 The oral bisphosphonates alendronate and 
risedronate are the most commonly used bisphosphonates, primarily prescribed 
for the prevention or treatment of osteoporosis.3 Reanalysis of clinical trial data of 
alendronate (FIT studies) showed a trend towards an increased risk of serious (though 
not all) AF events.4  However, analysis of adverse cardiovascular events in approxi-
Therapeutics and Clinical Risk Management 2011:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
132
Pazianas et al
mately 15,000  postmenopausal women in Phase III clinical 
trials of risedronate demonstrated no increased risk of AF, 
classified either as an adverse or serious adverse event, in 
the risedronate treated vs placebo group.5 Similar results 
have now been reported from a pooled analysis of all four 
ibandronate pivotal trials.6 Furthermore, based on reviews 
of safety data from placebo-controlled clinical trials, the 
US Food and Drug Administration announced that no clear 
association was observed between serious or nonserious AF 
and overall exposure to bisphosphonates.7
Retrospective epidemiological studies on the same 
issue have reported discordant results. A case control study 
of about 1,700 women from a state health care delivery 
system in the US during 2001–2004 showed that ever use 
of alendronate was associated with an increased risk of AF.8 
Another population-based study of about 81,700 women in 
Denmark during 1999–2005 showed that use of oral bispho-
sphonates (etidronate and alendronate) did not increase the 
risk of AF.9 However, a restricted cohort study from the same 
country (Denmark) by Abrahamsen et al showed an increased 
occurrence of AF in fracture patients treated with oral 
bisphosphonates.10 The higher risk of AF in  bisphosphonate 
treated patients, as the authors suggest, could be attributed to 
their increased baseline risk for cardiovascular events when 
compared with nonusers. In the United  Kingdom (UK), a 
case-series study showed no overall long-term increased risk 
of atrial fibrillation with use of alendronate and risedronate.11 
A meta-analysis by Loke et al12 showed that  bisphosphonate 
use is not associated with a significant increase in the risk 
of serious AF in postmenopausal women. However, a more 
recent meta-analysis that included the same studies as Loke’s 
et al,12 with the addition of the Abrahamsen et al findings10 
arrived at a conclusion that an association might exist.13 
 Interestingly, the Abrahamson et al data10 included a high 
proportion of bisphosphonate users compared to controls 
that had known risk factors for AF at the baseline; thus 
 modulating any impact of the bisphosphonates.
There are no proven mechanisms for this reported asso-
ciation between the use of bisphosphonates and increased 
incidence of AF. An extensive review of relevant pub-
lished studies examined the potential relationship between 
atrial arrhythmogenesis and the pharmacological action of 
 bisphosphonates.14 The authors concluded that evidence that 
 bisphosphonates affect atrial conduction is currently lacking 
but this might be an important area for further investigation.
Observational studies may be well suited for studying 
associations between commonly used drugs and adverse 
events.15,16 However, bias and confounding is inevitably a 
practical challenge. More replication studies are needed to 
scrutinize the association, if any, between oral bisphosphonate 
use and AF, because both AF and osteoporosis are very common 
conditions in the elderly.17,18 We conducted a retrospective 
cohort study using data from three large, independent 
databases in the US and the UK to determine if there was 
an association between the use of oral bisphosphonates 
alendronate and risedronate and incidence of AF.
Methods
Data source
We obtained data from three large, independent databases: 
MarketScan®, Ingenix®, and the Health Improvement Net-
work (THIN).
MarketScan refers to the MarketScan Commercial Claims 
and Encounters and Medicare Supplemental and Coordinator 
of Benefits databases. MarketScan obtains administrative data 
from approximately 45 large employers, health plans, and 
government and public organizations. Detailed information 
about the quality of diagnosis, procedure coding and data 
validation, as well as extensive application of these databases 
in health care research has been published elsewhere.19 As 
of December 2006, MarketScan represented the medical 
claims experience of 37 million people, of which 15 million 
were eligible for a medical claim. The MarketScan data was 
representative of the age and geographical distribution of 
the whole US population, with members residing primarily 
in the South (40%), as well as in the West (26%), Midwest 
(24%), and Northeast (10%).
Ingenix refers to Ingenix Lab/Rx Database® (Eden Prairie, 
MN). Ingenix obtains administrative data from managed-care 
health plans. As of December 2006, the Ingenix data con-
tained information on 35 million people of which 11 million 
were currently eligible for a medical claim. Compared to 
the whole US population, Ingenix data under-represented 
individuals aged 65 years and over, but covered a wide geo-
graphic area, with members residing primarily in the South 
(45%) and Midwest (27%), as well as in the West (15%) and 
Northeast (12%).
Both MarketScan and Ingenix contain longitudinal 
healthcare utilization data of individual patients, including: 
1) inpatient and outpatient clinical services specified by 
diagnostic codes of the International Classification of 
Diseases (ICD-9-CM), and procedure (mostly Current 
Procedural Terminology [CPT] codes); 2) retail and mail-
order pharmacy dispensations specified by national drug 
codes (NDC); and 3) demographic information including 
age, sex, and dates of eligibility for the respective health 
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plan. Both databases record fully adjudicated insurance 
claims for prescriptions filled by patients, and implement 
proprietary validation process, however, there is no guarantee 
that patients actually take the drug.
THIN is a large database of anonymous medical records 
collected at more than 300 general practices around the UK.20 
This longitudinal database is regularly updated and contains 
primary care data of 5.5 million individuals living in the UK. 
The patient population in THIN is broadly representative of 
the UK population. THIN is subject to a number of quality 
control standards to ensure consistent recording of important 
clinical outcomes and indicators. The quality of the database 
is monitored, and medical diagnoses in the database have 
high validity. THIN contains computerized data on patient 
demographics, medical encounters and diagnosis, prescrip-
tions, and additional health information. Clinical data and 
diagnoses are cataloged using Read Codes, a comprehensive 
classification scheme for medical conditions and symptoms. 
Prescriptions and therapies are entered using Multilex codes, 
which provide detailed information on the drug, dose, and 
route of administration.
Claims data of individual patients were de-identified 
in both Ingenix and MarketScan research databases in 
compliance with the US Health Insurance Portability and 
Accountability Act of 1996 (HIPAA). Ethical approval was 
obtained from the THIN Research Ethics Committee.
Study sample
In each of the three databases separately, we assembled a 
cohort of women according to their exposure to bisphospho-
nates between January 1st, 2002 and December 31st, 2005, 
as follows (Table 1). Bisphosphonate users included women 
who were between 50 and 89 years of age when they first 
received a prescription for alendronate or risedronate during 
this time period. The date of the first prescription of these 
drugs for each user was defined as the index date. For each 
user, up to four nonusers of the same age in years (based on 
year of birth) on the index date were randomly selected, and 
assigned the same index date as the user. These age-eligible 
nonusers were then checked for eligibility based on their 
medical history before the assigned index date. We decided 
to execute multiple rounds of this matching and checking 
process if necessary to avoid excluding more than 1% of users 
on account of no matching nonusers, two rounds of matching 
were done in the MarketScan and Ingenix databases, while 
one round achieved this in THIN.
To reduce exposure misclassification with respect to 
subsequent risk of incident AF, we required all women to 
have at least two years of continuous enrollment before the 
index date, during which time they must have no bisphos-
phonate prescriptions and at least one medical encounter. 
We also excluded women who had any of the following 
conditions during the two years before their index date: 
Table 1&UHDWLRQRIVWXG\FRKRUWVDFFRUGLQJWRRUDOELVSKRVSKRQDWHXVH
MarketScan (US)a Ingenix (US)a THIN (UK)
Users,  
N (%)
Nonusers,  
N (%)
Users,  
N (%)
Nonusers,  
N (%)
Users,  
N (%)
Nonusers, 
N (%)
Women aged 5089 on index date  
between 01/01/2002 and 12/31/2005
565,370  
(100%)
1,232,843  
(100%)
251,680  
(100%)
437,362  
(100%)
35,744  
(100%)
128,950  
(100%)
$ERYHKDYLQJDWOHDVWWZR\HDUVRI 
FRQWLQXRXVHQUROOPHQWEHIRUHLQGH[GDWH
213,234  
(37.7%)
825,928  
(67.0%)
84,834  
(33.7%)
302,931  
(69.3%)
34,125  
(95.5%)
117,704  
(91.3%)
Above, having at least one medical encounter  
and no bisphosphonate prescriptions during  
WZR\HDUVEHIRUHLQGH[GDWH
167,913  
(29.7%)
769,871  
(62.4%)
64,570  
(25.7%)
269,068  
(61.5%)
28,095  
(78.6%)
113,230  
(87.8%)
$ERYHKDYLQJQRGLDJQRVLVRI$)DQ\FDUGLDF 
dysrrhythmia, or antiarrhythmic prescriptions  
GXULQJWZR\HDUVEHIRUHLQGH[GDWH
151,488  
(26.8%)
686,944  
(55.7%)
53,049  
(21.1%)
221,118  
(50.6%)
24,666  
(69.0%)
85,572  
(66.4%)
$ERYHKDYLQJQRGLDJQRVLVRIK\SHUWK\URLGLVP 
hypothyroidism, alcoholism, or prescriptions  
RIWK\UR[LQ37+RUVWURQWLXPGXULQJ 
WZR\HDUVEHIRUHLQGH[GDWH
120,444  
(21.3%)
544,005  
(44.1%)
41,530  
(16.5%)
175,009  
(40.0%)
21,426  
(59.9%)
76,589  
(59.4%)
Above, having no oral glucocorticoid  
SUHVFULSWLRQVLQWZR\HDUVEHIRUHLQGH[GDWH
96,185  
(17.0%)
448,140  
(36.4%)
34,356  
(13.7%)
148,544  
(34.0%)
15,007  
(42.0%)
72,207  
(56.0%)
Above, with up to 4:1 matching  
RIQRQXVHUVWRXVHUV
95,228  
(16.8%)
352,627  
(28.6%)
33,907  
(13.5)
122,196  
(27.9%)
14,958  
(41.8%)
54,847  
(42.5%)
Note: a7ZRURXQGVRIPDWFKLQJZHUHXVHG
Abbreviation:$)DWULDOÀEULOODWLRQ
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supraventricular or ventricular arrhythmia (including 
pacemaker), hyperthyroidism, hypothyroidism, alcoholism, 
and prescriptions for antiarrhythmics, thyroxin, strontium, 
or oral glucocorticoids.
The study cohorts were followed for up to a maximum of 
three years from the index date until development of any of 
the study outcomes, ie, AF, any other cardiac dysrrhythmia 
(including palpitations, bradycardia, tachycardia, etc), pre-
scription of amiodarone, other antiarrhythmic drugs, or were 
censored for prespecified conditions, ie, death, disenrollment, 
treatment with oral glucocorticoids, thyroxin, strontium, use 
of any bisphosphonate (nonusers only), use of a different 
bisphosphonate than that at the index date (users only, except 
for switching between alendronate and risedronate in the 
combined analysis of the two drugs), diagnosis of alcohol-
ism, completion of three years follow up or December 31st 
of 2006, whichever came first.
Consistent with previous studies, AF diagnosis included 
ICD-9 codes 427.31 (AF) and 427.32 (atrial flutter) in the 
two US databases, and the READ codes 3272.00 (ECG: 
AF), 3273.00 (ECG: atrial flutter), G573.00 (AF and 
 flutter), G573000 (AF), and G573100 (atrial flutter) in 
the UK database. We empirically assumed that AF cases 
i dentified from hospital settings (including referral) were 
more severe. We also searched for electrocardiogram (ECG) 
procedures within one week before or after AF diagnosis, 
and assumed these cases were additionally supported with 
ECG evidence.
To explore a more liberal definition of AF based on pre-
scriptions of digoxin, warfarin, or amiodarone, we reviewed 
complete medical and drug history records available in the 
database of 100 randomly selected patients (50 users and 
50 nonusers). All recorded entries were exported to an Excel 
spreadsheet, except for bisphosphonate use, osteoporosis, 
and fracture diagnosis which were maintained in a blinded 
exposure status.
Our primary event of interest was incident AF. 
In addition, we also included any other cardiac  dysrrhythmia, 
or prescription of amiodarone as well as AF as part of a com-
posite secondary event of interest. To account for potential 
confounding factors, we also searched the medical and 
prescription drug history of the study subjects during the 
two years before the index date (considered as baseline) for 
the following conditions: angina, congestive heart failure, 
diabetes, fractures, any hospitalizations, hypertension, 
myocardial infarction, osteoporosis, renal diseases, stroke, 
thrombosis, prescriptions for ACE inhibitors, angiotensin 
receptor blockers (ARBs), anticoagulants, beta-blockers, 
calcium channel blockers, medications for cardiac ischemia, 
estrogens, diuretics, statins, total number of hospitalizations, 
and total number of all prescriptions.
Data analyses
Each study cohort from the three different databases was ana-
lyzed separately using the same approach outlined below.
Cox models for survival analysis were used to estimate 
the hazard ratios for AF (primary event of interest) and 
any dysrrhythmia (secondary event of interest) compar-
ing bisphosphonate users with their matched nonusers. 
All models were stratified on the matching variables: age 
and index date, with index date considered as the baseline. 
Potential confounders included both a prespecified list of 
potential important confounders based on the literature, and 
variables automatically selected using stepwise selection 
from a comprehensive list of variables using available records 
on inpatient and outpatient medical history, prescription 
drugs, and procedures in the three databases. Due to the large 
number of variables and weak assumptions on relevance to 
confounding, we used the Shtatland et al method21 for the 
stepwise variable selection for both AF and overall dysr-
rhythmia outcomes separately in the three databases (hence 
six sets of variables). All variables selected from any one or 
more of the six sets were kept in final model analysis. Of 
note, all of our prespecified key confounders were selected 
by the automatic approach. Proportional hazards assump-
tions were checked by fitting an interaction term between 
bisphosphonate use and follow-up time. We also checked 
that the selected confounders were not highly correlated (ie, 
multicollinearity).
Primary analysis compared all bisphosphonate users with 
their matched nonusers in the full study cohort. Secondary 
analyses were stratified according to 1) age at index date (฀$70 
vs ฀,70 years); 2) baseline heart disease (yes vs no), which 
included any diagnosis of angina, congestive heart failure, 
myocardial infarction, or other heart diseases; 3) baseline 
vascular disease and therapy (yes vs no), which included any 
diagnosis of stroke, thrombosis, or prescriptions for antico-
agulants or cardiac ischemic drugs; 4) baseline blood pressure 
therapy (yes vs no), which included any prescriptions for ACE 
inhibitors, ARBs, beta blockers, calcium channel blockers, or 
diuretics; 5) baseline fractures (yes vs no). These conditions 
were chosen for stratified analysis in order to assess whether 
any associations between bisphosphonate use and AF may 
be modified by (ie, depend on, or interact with) age or any 
major cardiovascular conditions, with somewhat arbitrary 
groupings that were not meant to be mutually exclusive.
Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
135
$WULDOÀEULOODWLRQDQGRUDOELVSKRVSKRQDWHV
Furthermore, we:
฀1฀.฀฀varied the definition of bisphosphonate users as requiring 
two or more prescriptions of the index drug (index 
date unchanged), which may reduce misclassification if 
some patients with only one recorded prescription may 
not have taken the drug;
฀2฀.฀฀evaluated whether there was a dose-response relationship 
in time-dependent Cox models that updated the total cumu-
lative number of bisphosphonate prescriptions monthly 
during follow-up as: 1, 2–10, ฀$11 prescriptions;
฀3฀.฀฀divided the follow-up periods into ฀,90 days, 90–179 days, 
180–364 days, and ฀$365 days since index to evaluate 
both relatively short and long risk windows.
We also separately analyzed alendronate and risedronate 
users as identified by the index prescription. As a  sensitivity 
analysis, we also tested two different designs of sample 
selections:
฀1฀.฀฀฀฀same selection of users, but nonusers were randomly 
selected with a 4:1 matching on age to users on 
01/01/2004, which was the midpoint of the time window 
for user selection, and assigned to all nonusers;
฀2฀.฀฀same selection of users, but AF event rates were compared 
in the three months before and three months after index 
date among the users only.
All analyses were performed using SAS (v 9.1; SAS 
Institute, Inc, Cary, NC). Two-sided P-values of ฀,0.05 
from likelihood ratio tests were considered as statistically 
significant, with no adjustment for multiple comparisons.
Results
The total number of oral nitrogen containing bisphosphonate 
users who met all the inclusion criteria in all three databases 
was calculated to be 144,093 with 529,670 age-matched 
controls. We identified 1,995 cases of AF (including severe) 
and 8,057 cases of any cardiac dysrrhythmia in the users 
group compared to 8,807 cases of AF (including severe) and 
32,712 cases of any cardiac dysrrhythmia in the nonusers.
The creation of the study cohorts is illustrated in Table 1. 
MarketScan was by far the largest database, followed by 
Ingenix and THIN. While up to one-third of nonusers and 
two-thirds of users in the two US claims databases were 
excluded based on less than two years of enrollment before 
the index date, fewer than 10% of women in THIN were 
excluded based on this criterion. Furthermore, only 5% of 
the users and 11% of the nonusers in the two US databases 
as well as 10% of the users and 21% of the nonusers from the 
THIN database were excluded because of previous diagnosis 
of AF or other dysrrhythmia.
General descriptions of the three study cohorts according 
to bisphosphonate use are provided in Table 2. Data available 
relating to follow-up and age at index date were more 
enriched in the THIN, followed by MarketScan and Ingenix. 
AF incidence was largest in MarketScan, followed by Ingenix 
and THIN. Median follow-up for users was shorter than 
the matched nonusers in all three databases. Among oral 
bisphosphonate users in all three databases, the most com-
mon oral bisphosphonate regimen was weekly (฀.90%), and 
the predominant days supply was for one month (฀.80%) 
with ฀,5% for three months. The reasons for censoring were 
similar for users and nonusers, with the exception of greater 
rates of bisphosphonate switching among users (about 10% 
in each database) than initiating bisphosphonates among 
nonusers (about 1% in each database) during follow-up (data 
not shown). Overall baseline medical and prescription drug 
history did not differ by more than 1%–2% between users 
and nonusers in all three databases, with the exception of 
osteoporosis (฀.20% more common among bisphosphonate 
users than nonusers). In all three databases, there were more 
nonusers than users with baseline diabetes, hypertension, or 
use of beta blockers. More bisphosphonate users were taking 
estrogens while no distinct patterns were noted for the rest 
of the baseline conditions. Risedronate users were generally 
older, and had an increased number of baseline cardiovascular 
diseases and medication use compared with alendronate users 
with a few exceptions (Table 2).
Overall, the primary analysis (multivariate adjusted 
models) in all three databases provided no evidence for 
an association between oral bisphosphonate use and AF in 
general, severe (hospitalized) cases alone, or ECG supported 
cases only. Furthermore, no association was detected when all 
dysrrhythmias were analyzed together. The overall hazard ratio 
for AF was 0.93 (0.88–0.99), P ฀= 0.02. Oral bisphosphonate 
use was associated with an adjusted 8% lower AF risk in 
the MarketScan database. Figure 1A and 1B illustrate the 
Kaplan–Meier estimates of the cumulative incidence curves 
for AF and dysrrhythmia, respectively. Hazard ratio estimates 
from all Cox models for AF in general, severe (hospitalized) 
cases or ECG supported cases, and dysrrhythmia are shown 
in Tables 3, 4, and 5, respectively. Variance inflation factors 
for all selected confounders were low (฀,2). In the two US 
databases, hazard ratio estimates for bisphosphonate use 
in patients older than 70 years of age appeared similar to 
estimates in younger patients. Furthermore, the hazard ratio 
estimates did not change when we compared bisphosphonate 
users to nonusers and the analysis was restricted to patients of 
80 years of age or older at the index date (Table 6).
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Table 2'HVFULSWLRQVRIWKHWKUHHVWXG\FRKRUWVDFFRUGLQJWRELVSKRVSKRQDWHXVH
MarketScan (US) Ingenix (US) THIN (UK)
ALN or RIS ALN RIS Nonusers ALN or RIS ALN RIS Nonusers ALN or RIS ALN RIS Nonusers
Total, N 95,228 59,026 36,202 352,627 33,907 21,241 12,666 122,196 14,958 11,047 3,911 54,847
Age at index, median 64 63 65 64 60 60 60 60 72 72 73 71
7RWDO3<RI)8 144,991 92,582 52,409 599,349 45,881 28,848 17,033 198,017 28,613 21,508 7,105 120,167
AF cases, N 1,480 903 577 6,521 356 251 105 1,628 159 127 32 658
AF incidence/1,000 PY 10.2 9.8 11.0 10.9 7.8 8.7 6.2 8.2 5.6 5.9 4.5 5.5
AF cases (hospital) 328 1,580 208 1,064 11 40
AF cases (ECG) 913 4,099 212 1,053 10 55
Any dysrrhythmia, Na 5,965 3,676 2,289 23,181 1,577 1,000 577 6,682 515 401 114 1,849
'D\VRI)8PHGLDQ 519 539 487 603 441 441 442 574 746 777 677 895
RIDOO5[PHGLDQ 28 27 31 29 22 21 23 19 44 42 50 28
RI%,65[PHGLDQ 5 5 4 NA 5 5 5 NA 9 9 8 NA
Weekly regimen, % 96.9 97.1 96.6 NA 97.3 97.5 96.8 NA 92.8 96.6 82.1 NA
Baseline medical history %*
Angina 2.4 2.3 2.7 2.7 1.9 1.7 2.0 2.0 2.3 2.2 2.4 2.1
CHF 2.3 2.1 2.5 2.7 1.4 1.3 1.4 2.1 1.0 0.9 1.3 0.7
Diabetes 9.8 9.4 10.6 14.7 8.6 8.5 8.9 14.4 4.4 4.2 5.0 6.4
Hospitalization 14.4 14.0 15.0 13.8 9.3 9.2 9.3 9.4 9.9 10.1 9.4 5.9
Hypertension 40.8 39.9 42.4 44.7 39.3 38.7 40.1 47.0 16.2 16.2 16.3 16.5
Osteoporosis 40.3 40.3 40.4 7.2 44.5 44.0 45.2 8.8 22.8 22.1 24.5 0.6
Other heart diseases 8.4 7.9 9.1 7.9 6.8 6.6 7.1 6.7 2.6 2.5 2.9 2.1
Renal disease 0.5 0.5 0.5 0.7 0.4 0.4 0.4 0.7 0.6 0.6 0.6 0.5
Stroke 3.9 3.7 4.3 3.8 2.1 2.0 2.2 2.1 0.8 0.8 0.9 0.7
Thrombosis 2.3 2.2 2.4 2.1 1.7 1.8 1.7 1.6 2.0 1.9 2.3 1.5
Baseline drug history, %*
ACE inhibitors 16.0 15.5 16.8 17.6 12.4 12.5 12.4 14.0 14.8 14.5 15.9 15.8
Anticoagulants 2.6 2.5 2.7 2.5 1.4 1.3 1.4 1.2 2.0 1.9 2.3 1.3
ARB 7.4 7.0 8.0 8.7 4.9 4.7 5.3 5.4 5.9 5.6 6.8 5.8
Beta-blockers 9.4 9.0 10.0 10.5 7.1 7.3 6.8 7.6 19.0 18.5 20.5 21.2
Ca2฀+-channel blockers 15.8 15.2 16.8 18.2 11.5 11.5 11.5 12.5 17.1 16.6 18.7 16.6
Diuretics 25.6 24.7 27.1 31.3 19.8 19.7 20.0 23.5 33.1 32.6 34.6 33.1
Estrogens 31.4 31.6 31.1 26.4 31.7 31.1 32.8 25.6 18.4 18.9 17.1 11.9
Anti-ischemic drugs 4.2 4.0 4.6 4.9 2.2 2.2 2.2 2.3 8.6 8.4 9.2 7.0
Statins 29.4 28.5 30.8 28.0 22.9 22.7 23.3 19.9 15.6 14.8 17.9 15.7
Notes: a,QFOXGLQJDWULDOÀEULOODWLRQDQ\RWKHUFDUGLDFG\VUUK\WKPLDRUSUHVFULSWLRQVIRUDPLRGDURQHP-values all ฀,ZLWKIHZH[FHSWLRQV
Abbreviations:$&(DQJLRWHQVLQFRQYHUWLQJHQ]\PH$)DWULDOÀEULOODWLRQ$/1DOHQGURQDWH$5%DQJLRWHQVLQUHFHSWRUEORFNHUV%,6ELVSKRVSKRQDWH&+)FRQJHVWLYHKHDUWIDLOXUH)8IROORZXS1$QRWDSSOLFDEOH3<SHUVRQ\HDUV
5,6ULVHGURQDWH5[SUHVFULSWLRQV
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Multivariate models confirmed that the risk factors for AF 
identified in our population are in agreement with the estab-
lished ones. Stratified analysis showed that AF risk, indepen-
dently of oral nitrogen containing-bisphosphonate use, was 
generally higher among women with known AF risk factors, 
including older age, cardiovascular diseases, and therapy. 
Interestingly, anticoagulants came up as the strongest risk 
factor. The absolute magnitude of the  hazard ratio associated 
with ever use vs never use of  anticoagulants at baseline was 
the largest (data not shown). Also, significant interactions 
were detected between bisphosphonate use and vascular 
disease in MarketScan and Ingenix, between bisphosphonate 
use and blood pressure therapies in MarketScan (Table 3) 
but no statistical interaction for  dysrrhythmia was detected. 
Statin use (yes vs no at baseline) showed a consistent 
favorable effect (hazard ratios about 0.8) in the present study, 
although we did not study men and did not measure duration 
or compliance.
When follow-up was broken up into four intervals, hazard 
ratios appeared to decrease overall with time since index 
date, although they did not exhibit well-ordered patterns 
in MarketScan and THIN. Dose-response analysis showed 
that each additional oral bisphosphonate prescription was 
significantly associated with a lower AF risk in Ingenix, 
but not in MarketScan and THIN. Sensitivity analysis using 
alternative study designs described in the methods section 
did not show significantly increased risk with oral bispho-
sphonate use. Corresponding results for all dysrrhythmias 
appeared similar, but corresponding hazard ratio estimates 
were generally larger.
Discussion
In our study, the biggest retrospective cohort study so far, 
the estimated incidence of AF was not increased in users 
of the oral bisphosphonates, alendronate or risedronate. 
Additionally, the risk factors for AF were no different 
from those already established, further supporting our 
conclusion. Equally pertinent is our observation that the 
mean age at which AF was diagnosed is the same for oral 
nitrogen containing bisphosphonate users as for nonusers. If 
bisphosphonate usage does in fact increase the risk of AF, 
we may expect to see a shift towards a younger age in the 
users group. Our study also shows no increased incidence 
of severe AF (hospitalized or ECG supported cases) in oral 
bisphosphonates users compared with nonusers. In contrast, 
in the HORIZON study1 where IV zoledronate was used, a 
statistically significant increase in severe AF was observed. 
Therefore, if indeed there is any real possibility that nitro-
gen containing bisphosphonates could cause AF, then, oral 
preparations should be placed at the lowest possible level of 
risk. Interestingly, combined analysis of all three databases 
showed that use of oral bisphosphonates was associated with 
a statistically significant risk reduction in AF. It is beyond 
the scope of the present study to investigate whether osteo-
porosis treatment actually results in cardiovascular benefits, 
and whether such benefits are clinically significant.
In all three databases, we found no increased risk of 
AF with use of oral bisphosphonates (alendronate and rise-
dronate), consistent with the largest case-control study of 
Sorensen et al,9 the UK case series study using the General 
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Table 3+D]DUGUDWLRFRQÀGHQFHLQWHUYDOHVWLPDWHVIRU$)FRPSDULQJELVSKRVSKRQDWHXVHUVWRPDWFKHGQRQXVHUV
Database MarketScan (US) Ingenix (US) THIN (UK)
Index drug ALN or RIS ALN RIS ALN or RIS ALN RIS ALN or RIS ALN RIS
8QDGMXVWHG 0.92 (0.870.98) 0.91 (0.840.98) 0.94 (0.851.03) 0.96 (0.851.09) 1.06 (0.911.24) 0.78 (0.620.97) 0.93 (0.781.12) 0.99 (0.801.21) 0.92 (0.870.98)
Adjusted 0.92 (0.850.99)a 0.93 (0.851.02) 0.90 (0.801.01) 1.00 (0.871.16) 1.12 (0.941.34) 0.79 (0.621.03) 0.97 (0.791.20) 1.02 (0.811.28) 0.86 (0.541.37)
BIS Rx ฀$฀฀2 0.86 (0.790.93)a 0.89 (0.800.98)a 0.82 (0.720.93)a 0.96 (0.821.13) 1.09 (0.901.33) 0.71 (0.520.95)a 0.98 (0.791.23) 1.03 (0.801.31) 0.88 (0.541.44)
Age
฀$70 0.95 (0.881.04) 0.96 (0.861.06) 0.93 (0.811.06) 1.01 (0.841.20) 1.17 (0.951.44) 0.71 (0.510.99) 1.07 (0.861.33)b 1.14 (0.891.45)b 0.88 (0.551.43)
฀,70 0.85 (0.740.98) 0.87 (0.741.03) 0.83 (0.671.03) 1.03 (0.801.32) 1.05 (0.791.39) 0.93 (0.641.35) 0.33 (0.130.82)b 0.35 (0.150.83)b 0.67 (0.182.48)
Heart disease
Yes 0.94 (0.811.09) 0.92 (0.761.11) 0.97 (0.781.22) 0.97 (0.691.36) 1.10 (0.711.69) 0.75 (0.431.32) 0.51 (0.241.08) 0.37 (0.160.88)b 2.04 (0.3212.80)
No 0.91 (0.840.99) 0.94 (0.841.04) 0.87 (0.761.00) 1.01 (0.861.18) 1.12 (0.931.36) 0.80 (0.601.06) 1.03 (0.831.28) 1.12 (0.881.42)b 0.84 (0.531.35)
Vascular disease
Yes 1.75 (1.551.97)b 1.69 (1.441.98)b 1.83 (1.522.20)b 1.98 (1.452.71)b 2.30 (1.583.34)b 1.39 (0.772.51)b 1.09 (0.701.71) 1.06 (0.641.73) 1.10 (0.363.34)
No 0.74 (0.680.80)b 0.77 (0.690.85)b 0.70 (0.610.80)b 0.91 (0.781.06)b 1.04 (0.861.26)b 0.71 (0.540.94)b 0.95 (0.761.19) 1.01 (0.781.30) 0.82 (0.501.34)
Blood pressure drugs
Yes 1.00 (0.921.09)b 1.03 (0.921.16) 0.96 (0.841.10)b 1.04 (0.861.25) 1.18 (0.941.47) 0.77 (0.551.09) 1.01 (0.791.30) 1.07 (0.811.41) 0.88 (0.511.51)
No 0.78 (0.690.88)b 0.77 (0.660.90) 0.80 (0.650.97)b 0.97 (0.791.20) 1.05 (0.811.36) 0.85 (0.591.22) 0.87 (0.621.21) 0.93 (0.641.34) 0.66 (0.301.44)
Fracture
Yes 1.05 (0.841.31) 1.20 (0.901.60) 0.93 (0.471.84) 1.41 (0.902.21) 1.74 (1.003.05) 0.85 (0.601.21) 0.82 (0.451.50) 0.93 (0.471.84) 1.00 (0.472.15)
No 0.90 (0.811.11) 0.90 (0.810.99) 0.98 (0.751.27) 0.95 (0.811.11) 1.06 (0.881.28) 0.90 (0.801.02) 0.94 (0.741.19) 0.98 (0.751.27) 0.76 (0.581.00)
Follow-up (days) since index
฀,90 0.94 (0.831.07) 0.95 (0.801.12) 0.93 (0.761.14) 1.33 (1.021.75) 1.37 (0.991.91) 1.24 (0.771.99) 1.00 (0.571.77) 1.11 (0.592.08) 0.67 (0.172.65)
90179 0.86 (0.731.01) 0.83 (0.671.03) 0.90 (0.701.16) 1.23 (0.921.66) 1.33 (0.921.94) 1.05 (0.651.71) 0.87 (0.501.49) 0.95 (0.531.71) 0.54 (0.122.42)
180364 0.93 (0.811.07) 0.92 (0.771.10) 0.94 (0.751.17) 0.77 (0.591.02) 0.95 (0.691.31) 0.45 (0.250.81) 0.88 (0.591.30) 0.83 (0.531.30) 1.07 (0.442.64)
฀$365 0.92 (0.821.04) 0.97 (0.841.13) 0.84 (0.691.03) 0.89 (0.701.12) 1.02 (0.771.37) 0.68 (0.441.04) 1.04 (0.791.37) 1.12 (0.821.53) 0.90 (0.501.64)
# of BIS prescriptions
1 1.13 (1.011.28) 1.11 (0.951.30) 1.16 (0.971.40) 1.47 (1.161.86) 1.62 (1.212.19) 1.20 (0.801.80) 1.05 (0.641.74) 1.12 (0.641.96) 0.80 (0.252.56)
210 0.83 (0.760.91) 0.83 (0.740.94) 0.83 (0.720.96) 0.88 (0.731.07) 0.97 (0.771.22) 0.73 (0.521.03) 0.85 (0.651.12) 0.93 (0.691.26) 0.58 (0.291.15)
฀$11 0.91 (0.731.13) 1.08 (0.831.40) 0.61 (0.410.92) 0.78 (0.521.16) 1.10 (0.691.74) 0.29 (0.110.75) 1.23 (0.821.83) 1.26 (0.802.00) 1.31 (0.572.98)
Per 1 more 0.98 (0.970.99)c 0.99 (0.981.00) 0.97 (0.950.99)c 0.99 (0.971.00) 1.00 (0.981.02) 0.96 (0.930.99)c 1.00 (0.991.02) 1.00 (0.981.02) 1.02 (0.991.06)
Notes: aP ฀,IRUOLNHOLKRRGUDWLRWHVWbP ฀,IRUWHVWRILQWHUDFWLRQRUHIIHFWPRGLÀFDWLRQcP ฀,IRUWUHQGWHVWZLWKQXPEHURIELVSKRVSKRQDWHSUHVFULSWLRQVDVDFRQWLQXRXVYDULDEOH0RGHODGMXVWHGYDULDEOHVKLVWRU\RIDQJLQD
FRQJHVWLYHKHDUWIDLOXUHGLDEHWHVDQ\KRVSLWDOL]DWLRQVK\SHUWHQVLRQP\RFDUGLDOLQIDUFWLRQRVWHRSRURVLVUHQDOGLVHDVHVVWURNHWKURPERVLVSUHVFULSWLRQVIRU$&(LQKLELWRUVDQJLRWHQVLQUHFHSWRUEORFNHUVDQWLFRDJXODQWVEHWDEORFNHUV
FDOFLXPFKDQQHOEORFNHUVPHGLFDWLRQVIRUFDUGLDFLVFKHPLDHVWURJHQVGLXUHWLFVVWDWLQVDQGWRWDOQXPEHURIDOOSUHVFULSWLRQV
Abbreviations:$)DWULDOÀEULOODWLRQ$/1DOHQGURQDWH%,6ELVSKRVSKRQDWH+5KD]DUGUDWLR1$QRWDSSOLFDEOH5,6ULVHGURQDWH5[SUHVFULSWLRQ
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Practice Research Database (GPRD),11 and published data on 
a placebo-controlled clinical trial of risedronate for the treat-
ment of osteoporosis.5 In contrast, Heckbert et al8 reported 
an overall increased risk of AF associated with alendronate. 
Cases in that study were four years older than controls in 
median age, and had significantly more prevalent AF risk 
factors. In fact, our stratified analyses showed a general ten-
dency toward larger hazard ratios among women who were 
older or had cardiovascular risk factors. It is possible that 
women with baseline stroke, thrombosis, or prescriptions 
for anticoagulants or cardiac ischemic drugs had prevalent 
undiagnosed AF. Among women who were younger or had 
no baseline cardiovascular risk factors, however, the hazard 
ratio estimates which were not confounded by these risk 
factors were consistently lower.
We identified ECG supported AF diagnosis as well as 
cases identified in hospital settings. The results of Cox models 
on these presumably more specific AF outcomes were very 
similar to the primary analysis. In addition, the relative risks 
estimated for established risk factors were generally consis-
tent in magnitude with those reported in previous studies. 
The incidence rates of AF diagnosis seemed higher in the 
two US databases than THIN, even though THIN patients 
were older. Although there have been reports of increasing 
trend of AF incidence in the US,17,22 we cannot confirm if 
the difference we observed between the two countries is 
real. The fact that more prevalent AF cases were excluded in 
THIN than in the two US databases may in part explain the 
difference, and it is possible that some AF cases in the US 
databases were actually prevalent or silent AF cases instead 
of incident ones. On the other hand, the prevalence of sus-
tained silent AF in people over the age of 65 is believed to 
be 25%–30% or even higher,23 and therefore, both our study 
and previous ones may have missed many incident cases and 
included prevalent cases.
We found no increased hazard ratio for AF or cardiac 
dysrrhythmias in bisphosphonates users older than 70 years 
of age (Tables 3 and 5). Even when we restricted our 
comparison of bisphosphonate users with nonusers to patients 
who were 80 years of age or older, the hazard ratio did not 
become significant (Table 6). However, our sample size and 
statistical power was limited in this age group.
Hazard ratio estimates for AF and dysrrhythmia sug-
gested a significant interaction between bisphosphonate use 
and vascular disease in MarketScan and Ingenix databases 
(Tables 3 and 5). This finding could well be related to the 
identification of anticoagulants as the strongest risk factor 
for AF in both groups, ie, users and nonbisphosphonate 
users. Also, a significant interaction was detected between 
bisphosphonate use and blood pressure therapies, albeit in 
MarketScan database only. It is interesting that in nonbis-
phosphonate users in all three databases, such blood pressure 
medications have been implicated as risk factors for AF and 
cardiac dysrrhythmias as well. This is contrary to the current 
understanding that, for example, ACE inhibitors/ARBs have 
a protective effect.
It is of interest to evaluate whether the initiation of bis-
phosphonates triggers a transient increase in the risk of AF, 
which appeared higher following one prescription of a bis-
phosphonate, even though overall dose-response relationship 
appeared negative in our study. Neither of the two sensitivity 
analyses in a short risk window (follow-up ฀,90 days, and 
risk in three months before and after bisphosphonate use) 
found any significant evidence for increased AF incidence 
among bisphosphonate users. From the time-dependent 
Cox model, women who had one prescription only may 
experience AF long after the prescription date (eg, one year 
later). These patients may have higher risk of AF due to poor 
general health and noncompliance with their therapy. In a 
sensitivity analysis (not shown) that excluded women with 
one prescription only, the corresponding HR estimates in 
time-dependent Cox models associated with one prescription 
were all diminished. Another reason for caution is that 
in electronic databases, filling a prescription (the two US 
databases) or receiving a prescription (UK database) is not 
equivalent to patients actually taking the drug. As shown 
in a subanalysis of users with two or more prescriptions 
of bisphosphonates and their matched nonusers (Tables 3 
and 5), hazard ratio estimates decreased after excluding the 
one prescription only users. The initiation of bisphosphonate 
therapy may arise from increasing health care encounters and 
result in early detection and diagnosis of AF during checkup, 
which may also help to explain the apparent increased risk 
of AF following one prescription. In the HORIZON study, 
AF events did not cluster immediately after zoledronic acid 
infusion, but rather occurred evenly over the three-year 
period of the study.1,24,25 In our study, the time to AF onset 
Table 4+D]DUGUDWLRFRQÀGHQFHLQWHUYDOIRUDKRVSLWDOL]HG
$)FDVHVDQGE(&*FRQÀUPHG$)FDVHV
MarketScan Ingenix THIN 
a)
0.89 (0.771.03) 0.96 (0.801.16) 0.96 (0.372.51)
b)
0.92 (0.841.00) 0.94 (0.781.13) 0.64 (0.281.46)
Abbreviations:$)DWULDOÀEULOODWLRQ(&*HOHFWURFDUGLRJUDP
T
h
erap
eu
tics an
d
 C
lin
ical R
isk M
an
agem
en
t 2
0
1
1
:7
su
b
m
it yo
u
r m
a
n
u
sc
rip
t | w
w
w
.d
o
vep
ress.co
m
D
o
v
e
p
re
ss 
D
o
v
e
p
re
ss
1
4
0
P
azian
as et al
Table 5+D]DUGUDWLRFRQÀGHQFHLQWHUYDOHVWLPDWHVIRUDQ\G\VUUK\WKPLDFRPSDULQJELVSKRVSKRQDWHXVHUVWRPDWFKHGQRQXVHUV
Database MarketScan (US) Ingenix (US) THIN (UK)
Index drug ALN or RIS ALN RIS ALN or RIS ALN RIS ALN or RIS ALN RIS
8QDGMXVWHG 1.05 (1.021.08) 1.04 (1.001.08) 1.07 (1.021.13) 1.03 (0.971.09) 1.02 (0.951.10) 1.03 (0.941.14) 1.16 (1.051.29) 1.17 (1.041.31) 1.13 (0.911.40)
Adjusted 1.01 (0.981.05) 1.01 (0.971.06) 1.01 (0.961.07) 1.06 (0.991.13) 1.07 (0.991.17) 1.02 (0.911.15) 1.12 (0.991.26) 1.13 (0.991.29) 1.10 (0.851.42)
$GMXVWHGGHÀQH 
anti-arrhythmics rx
1.03 (1.001.07)a 1.03 (0.991.08) 1.03 (0.981.09) 1.10 (1.031.17)a 1.13 (1.051.22)a 1.04 (0.941.15) 1.08 (0.981.19) 1.10 (0.991.23) 1.01 (0.821.24)
BIS Rx ฀$฀฀2 0.96 (0.921.00)a 0.96 (0.921.01) 0.95 (0.901.02) 1.02 (0.951.10) 1.04 (0.951.14) 0.98 (0.861.11) 1.11 (0.981.25) 1.12 (0.971.29) 1.08 (0.821.42)
Age
฀$70 0.98 (0.941.03)b 0.99 (0.931.05) 0.98 (0.911.05) 1.08 (0.981.19) 1.12 (0.991.25) 0.99 (0.841.17) 1.08 (0.941.24) 1.11 (0.951.30) 0.99 (0.731.35)
฀,70 1.05 (1.001.11)b 1.05 (0.981.12) 1.07 (0.981.16) 1.05 (0.961.14) 1.04 (0.931.16) 1.05 (0.911.20) 1.19 (0.991.43) 1.16 (0.941.43) 1.33 (0.901.95)
Heart disease
Yes 0.96 (0.891.04) 0.99 (0.901.09) 0.92 (0.821.03) 1.02 (0.851.22) 0.97 (0.771.22) 1.10 (0.831.47) 0.80 (0.521.22) 0.71 (0.441.15) 1.23 (0.512.98)
No 1.03 (0.991.07) 1.02 (0.971.07) 1.04 (0.981.11) 1.07 (0.991.15) 1.09 (0.991.19) 1.01 (0.891.14) 1.15 (1.021.30) 1.17 (1.021.35) 1.11 (0.851.45)
Vascular disease
Yes 1.38 (1.291.49)b 1.38 (1.261.52)b 1.38 (1.231.54)b 1.44 (1.191.74)b 1.60 (1.272.03)b 1.18 (0.851.63) 1.17 (0.891.53) 1.07 (0.781.46) 1.60 (0.912.83)
No 0.94 (0.900.98)b 0.94 (0.900.99)b 0.93 (0.880.99)b 1.03 (0.961.10)b 1.04 (0.951.13)b 1.00 (0.891.13) 1.11 (0.981.26) 1.14 (0.991.31) 1.03 (0.781.36)
Blood pressure drugs
Yes 1.02 (0.971.06) 1.02 (0.971.08) 1.00 (0.931.08) 1.13 (1.031.24) 1.17 (1.041.31) 1.06 (0.901.23) 1.10 (0.941.28) 1.10 (0.931.31) 1.08 (0.781.49)
No 1.01 (0.961.07) 1.00 (0.941.07) 1.03 (0.951.12) 1.01 (0.921.10) 1.01 (0.901.13) 0.99 (0.851.16) 1.11 (0.941.31) 1.13 (0.941.36) 1.05 (0.731.52)
Fracture
Yes 1.06 (0.941.19) 1.12 (0.961.30) 0.96 (0.801.17) 1.28 (0.991.65) 1.31 (0.961.80) 1.22 (0.791.88) 0.92 (0.631.35) 0.91 (0.581.41) 0.85 (0.381.89)
No 1.01 (0.981.05) 1.01 (0.961.06) 1.02 (0.961.08) 1.04 (0.971.12) 1.06 (0.971.15) 1.01 (0.901.14) 1.14 (1.011.30) 1.17 (1.011.35) 1.10 (0.831.46)
Follow-up (days) since index
฀,90 1.01 (0.941.08) 1.06 (0.971.15) 0.94 (0.841.05) 1.04 (0.901.20) 1.05 (0.881.25) 1.01 (0.801.28) 0.95 (0.691.30) 1.03 (0.721.46) 0.72 (0.341.54)
90179 0.94 (0.871.02) 0.97 (0.881.07) 0.89 (0.781.01) 1.17 (1.011.35) 1.19 (0.991.44) 1.12 (0.881.42) 1.36 (1.011.81) 1.27 (0.901.79) 1.70 (0.982.95)
180364 1.05 (0.991.12) 1.02 (0.941.11) 1.11 (1.001.23) 1.05 (0.931.19) 1.06 (0.911.23) 1.04 (0.851.27) 1.12 (0.901.39) 1.16 (0.911.48) 1.00 (0.621.60)
฀$365 1.03 (0.971.09) 1.01 (0.941.08) 1.06 (0.971.16) 1.03 (0.931.14) 1.05 (0.921.20) 0.97 (0.811.16) 1.10 (0.941.29) 1.11 (0.931.32) 1.09 (0.781.54)
# of BIS prescriptions
1 1.24 (1.171.32) 1.25 (1.161.35) 1.23 (1.121.35) 1.30 (1.161.47) 1.33 (1.141.54) 1.25 (1.031.53) 1.38 (1.051.80) 1.37 (1.011.86) 1.32 (0.722.41)
210 0.94 (0.900.98) 0.94 (0.891.00) 0.93 (0.871.00) 1.01 (0.931.10) 1.00 (0.901.12) 1.02 (0.891.18) 1.07 (0.921.24) 1.08 (0.911.28) 1.05 (0.761.45)
฀$11 0.93 (0.841.04) 0.92 (0.811.04) 0.96 (0.811.14) 0.90 (0.751.09) 1.09 (0.881.37) 0.60 (0.430.85) 1.14 (0.901.44) 1.12 (0.861.47) 1.26 (0.782.02)
Each 1 more 0.99 (0.991.00)c 0.99 (0.991.00)c 0.99 (0.991.00) 1.00 (0.991.00) 1.00 (0.991.01) 0.99 (0.981.01) 1.00 (0.991.01) 1.00 (0.991.01) 1.01 (0.991.03)
Notes: aP ฀,IRUOLNHOLKRRGUDWLRWHVWbP ฀,IRUWHVWRILQWHUDFWLRQRUHIIHFWPRGLÀFDWLRQcP ฀,IRUWUHQGWHVWZLWKQXPEHURIELVSKRVSKRQDWHSUHVFULSWLRQVDVDFRQWLQXRXVYDULDEOH0RGHODGMXVWHGYDULDEOHVKLVWRU\RIDQJLQD
FRQJHVWLYHKHDUWIDLOXUHGLDEHWHVDQ\KRVSLWDOL]DWLRQVK\SHUWHQVLRQP\RFDUGLDOLQIDUFWLRQRVWHRSRURVLVUHQDOGLVHDVHVVWURNHWKURPERVLVSUHVFULSWLRQVIRU$&(LQKLELWRUVDQJLRWHQVLQUHFHSWRUEORFNHUVDQWLFRDJXODQWVEHWDEORFNHUV
FDOFLXPFKDQQHOEORFNHUVPHGLFDWLRQVIRUFDUGLDFLVFKHPLDHVWURJHQVGLXUHWLFVVWDWLQVDQGWRWDOQXPEHURIDOOSUHVFULSWLRQV
Abbreviations:$/1DOHQGURQDWH%,6ELVSKRVSKRQDWH+5KD]DUGUDWLR1$QRWDSSOLFDEOH5,6ULVHGURQDWH5[SUHVFULSWLRQ
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was not evenly distributed in all three databases and AF 
onset occurred later in time. Among bisphosphonate users, 
about 27%, 23%, and 11% of AF occurred within first three 
months of the index date, 35%, 37%, and 57% after one year 
after the index date in the MarketScan, Ingenix, and THIN 
databases, respectively. When we divided follow-up into 
four intervals, only the Ingenix data suggested an increased 
risk of AF shortly after initiation of bisphosphonate therapy. 
Further analysis showed that the short-term increased risk of 
AF mostly occurred in bisphosphonate users who received 
only one prescription. The baseline cardiovascular risk 
factors were more prevalent among these patients. Overall 
data from all three databases did not suggest oral bisphos-
phonates as an acute trigger for AF events. It is interesting 
that although risedronate users in all three databases were 
slightly older than alendronate users, and had in general 
more cardiovascular risk factors, use of risedronate did not 
show an increased risk shortly after index date, except in the 
Ingenix database.
In previous studies, no dose-response relationship was 
observed for alendronate8 or zoledronic acid1 in association 
with AF. In our dose-response analysis, we actually observed 
a significantly lower risk of AF with more use of bisphos-
phonates in the two US databases. The Danish case-control 
study and the present study also did not show any trends 
toward greater risk of AF with larger cumulative dosing 
or more recent use of oral bisphosphonates. Paradoxically, 
stratified analysis in the Heckbert et al study showed that past 
but not current use of alendronate was associated with AF, 
with a median time since the last alendronate prescription of 
1.3 years among cases and 0.8 years among controls.8
Inflammatory events are also associated with AF26 and 
increased levels of inflammatory markers have been observed 
both in the acute-phase responses to bisphosphonates27,28 and 
AF.29 Treatment with potent anti-inflammatory medications 
could modify the risk of arrhythmias and thus the outcome of 
studies on AF. We assessed the effects of statins, a group of 
agents with anti-inflammatory properties and potentially pre-
ventive effects in the development of AF. Our study supports 
a protective role for statins whereas the Heckbert et al study 
showed higher risk of AF in patients currently taking statins.8
Glucocorticoids, another group of potent anti- inflammatory 
medications, reduce the release of several inflammatory and 
acute-phase response mediators but their use is associated 
with an increased risk of myocardial infarction, stroke, and 
heart failure, which are also risk factors for AF. A recent 
report suggested that current use of systemic glucocorticoids 
is associated with an almost twofold increased risk of AF 
or flutter.30 Interestingly, a significant number of patients on 
glucocorticoids are treated with an oral bisphosphonate for 
the prevention or treatment of osteoporosis. In our study we 
excluded patients on glucocorticoid treatment, especially as 
in our initial selection of patients twice as many of the bis-
phosphonate users were taking oral glucocorticoids compared 
to controls (Table 1).
Strengths and limitations of study
The strengths of our study include the large sample size 
(larger than the four studies published so far), application 
of the same methods to three independent databases of two 
developed countries, and control of important confounders, 
ie, age and gender. Studying the three databases separately 
enabled us to examine the reproducibility of findings in our 
own study as well as in other previous studies. Consistency 
of results across different populations and studies is an impor-
tant consideration in epidemiology.32 Because of different 
health care systems and data structure of the three databases, 
keeping them separate helps avoid any particular information 
bias in one database to be repeated in the others. We note 
that some apparent differences in prevalence of comorbidities 
between the two countries (eg, osteoporosis, angina, CHF, 
diabetes) may at least in part due to underascertainment or 
underrecording of the conditions.
Our study period of 2002–2006 overlaps with those of 
previous observational studies, ie, before the publication 
of the HORIZON clinical trial, and thus, is not likely to 
be subject to greater reporting of AF among users. On the 
other hand, this calendar time constraint combined with a 
high turnover rate in our study (especially the two claims 
databases) limited our ability to extrapolate the results to 
more than three years of bisphosphonate therapy.
Our study also has other limitations, including lack of 
sufficient clinical details to confirm AF outcomes or to 
Table 6 +D]DUG UDWLR  FRQÀGHQFH LQWHUYDO HVWLPDWHV
comparing bisphosphonate users (alendronate and risedronate) 
WRQRQXVHUVUHVWULFWHGWRSDWLHQWVRI\HDUVRIDJHRUROGHUDW
the index date
P-value Hazard  
ratio
Lower Upper
MarketScan, AF 0.10 1.10 0.98 1.25
Ingenix, AF 0.69 1.05 0.82 1.35
THIN, AF 0.81 0.96 0.72 1.29
MarketScan,  
all dysrrhythmias
0.42 1.03 0.96 1.10
Ingenix, all dysrrhythmia 0.13 1.12 0.97 1.31
THIN, all dysrrhythmia 0.21 1.15 0.93 1.42
Abbreviation:$)DWULDOÀEULOODWLRQ
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control for disease severity of osteoporosis and cardiovascular 
disease. It is also possible that prevalent AF and other disease 
conditions were not fully captured in the two years of history 
before index. The impact of such measurement bias may be 
small.
Confounding by indication may not be adequately 
controlled. Osteoporosis is a risk factor for AF. Bisphos-
phonates are indicated for the treatment of osteoporosis. 
Thus therapy with bisphosphonates may be associated with 
incidence of AF. Osteoporosis has been shown to be a risk 
factor for incident cardiovascular events, independent of 
age, diabetes, hypertension, hyperlipidemia, smoking, and 
prior CHD events.16,24,31 Therefore bisphosphonate therapy 
may be statistically associated with adverse cardiovascular 
outcomes through its indication for osteoporosis alone. To 
alleviate such confounding by indication, it is important 
to assess the specificity of any associations. For example, 
we explored the specificity of AF case definition based on 
prescription of warfarin and digoxin. Blinded review with 
respect to bisphosphonate exposure ruled out 44 (88%) of 
the 50 randomly selected nonusers and 40 (90%) of the 50 
randomly selected users as likely to be other cardiovascular 
events instead of AF. Furthermore, we evaluated a compos-
ite outcome defined by any cardiac dysrrthymia diagnosis 
or antiarrhythmic prescriptions (listed in Appendix 1), the 
number of cases so defined increased fivefold of that for 
AF cases, and hazard ratio estimates for bisphosphonate 
use overall were slightly larger (results not shown). Such a 
composite outcome likely represented diverse cardiovascular 
disorders. One of the most commonly used criteria to judge 
causality involves specificity in the association between a risk 
factor and outcome. If bisphosphonates truly caused AF, we 
would generally expect to see a less distinctive association 
when outcomes became less specific.
We note that in all three databases, a greater percent-
age of nonusers either had a full three-year follow-up or 
reached the end of the study (ie, administrative censoring) 
(54%, 33%, and 77% in MarketScan, Ingenix and THIN, 
respectively) than users (39%, 25%, and 61% in Mar-
ketScan, Ingenix, and THIN, respectively), and that users 
were more likely to encounter the censoring events such 
as switching therapy, receiving glucocorticoid therapy, 
parathyroid hormone, or thyroxine which may alter the 
risk of AF (independent of bisphosphonates). Although 
we didn’t directly assess the impact of this censoring on 
our primary analysis, sensitivity analysis using alternative 
design yielded similar results. Technically, the numerical 
magnitude of the longer follow-up in nonusers than users 
may not have as much real impact on the Cox models, which 
rely on the ranking of event times rather than the actual 
length of follow-up. Finally, our study is an observational 
study and therefore causality cannot be assumed. Further-
more, our findings cannot be extrapolated to male patients 
or patients older than 90 years of age.
In conclusion, we found that the use of oral bisphospho-
nates was not associated with an increased incidence of AF. 
The considerable size of the populations we studied derived 
from two different countries increases our confidence that our 
findings reflect the clinical reality in medical practice.
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Appendix 1
Antiarrhythmics (including various formulations or 
compounding)
Adenosine, atropine, bretylium tosylate,  disopyramide, 
dofetilide, encainide, flecainide, ibutilide,  lidocaine, 
 lignocaine, mexiletine, moracizine, procainamide, 
 propranolol, quinidine, sotalol, tocainide, verapamil.
